kalvista - Search News

News

KalVista, FDA and EKTERLY

Reuters on MSN · 1d

US FDA approves KalVista's oral swelling disorder drug, shares rise

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares up more than 18%.

PharmExec · 13h

FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older.

Seeking Alpha · 6h

KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

KalVista Wins OK for First On-Demand Hereditary Angioedema Pill

Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...

1d

Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)

Orsini, a leader in rare disease pharmacy solutions, has been chosen by KalVista Pharmaceuticals as a specialty pharmacy ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results